Compare ORA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORA | CRSP |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.8B |
| IPO Year | 2004 | 2016 |
| Metric | ORA | CRSP |
|---|---|---|
| Price | $87.98 | $38.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 23 |
| Target Price | ★ $116.46 | $85.42 |
| AVG Volume (30 Days) | 631.3K | ★ 1.5M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $719,267,000.00 | $289,590,000.00 |
| Revenue This Year | $20.02 | $910.97 |
| Revenue Next Year | N/A | $277.83 |
| P/E Ratio | $55.14 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $85.77 | $39.80 |
| 52 Week High | $146.39 | $63.45 |
| Indicator | ORA | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 26.78 |
| Support Level | $86.41 | N/A |
| Resistance Level | $97.89 | $60.68 |
| Average True Range (ATR) | 2.66 | 2.46 |
| MACD | -0.23 | -0.95 |
| Stochastic Oscillator | 9.17 | 0.54 |
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: the Electricity Segment. where the company develops, builds, owns, and operates geothermal, solar PV, and recovered energy-based power plants in the United States and geothermal power plants in other countries and sells the electricity generated. Product Segment includes designing, manufacturing, and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement, and construction of geothermal & recovered energy-based power plants. Energy Storage Segment includes owning & operating grid-connected which provide capacity, energy, & ancillary services directly to the electric grid.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.